Fused bicyclic (hetero)aromatic compounds useful for the treatment of cancers
USRE49361E1 · kind E1 · reissue
0Cited by
1References
24Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 24, 2020 |
| Grant date | Jan 10, 2023 |
| Priority date | — |
| Expiry date | Nov 24, 2040 |
Classification
- Technology area (CPC —)General
Abstract
This invention relates to novel compounds. The compounds of the invention are kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Raf kinases, e.g., B-Raf and C-Raf. The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Raf kinases, for example, cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.